GlassScriptPhysician profile
Adam C Kenney
NPI 1083956114
$4,910.21
in general payments reported to CMS, 2019-2025
18 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,352 · 2022: $41.20 · 2023: $431 · 2024: $524 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,097.31 | 2021-2024 | Intellis Adaptivestim, Minimed 780g |
| Scilex Pharmaceuticals INC. | $361.43 | 2022-2025 | Ztlido |
| Zynex Medical, INC. | $276.51 | 2025 | Nexwave |
| Collegium Pharmaceutical, INC. | $196.83 | 2023-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $194.33 | 2021-2025 | Proclaim, Ensite Derexi |
| Boston Scientific Corporation | $173.96 | 2021 | |
| Nevro Corp. | $135.37 | 2021 | |
| Abbvie INC. | $127.11 | 2022-2025 | |
| Relievant Medsystems, INC. | $59.71 | 2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.99 | 2022-2025 | Relistor |
| Biotronik Nro, INC. | $53.03 | 2024-2025 | Prospera |
| Ibsa Pharma INC. | $51.40 | 2023 | Tirosint, Licart |
| Ucb, INC. | $34.79 | 2023-2024 | Cimzia |
| Si-Bone, INC. | $27.08 | 2023 | |
| Azurity Pharmaceuticals, INC. | $21.28 | 2023 | Horizant |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $15.27 | 2023 | Krystexxa |
| International Rehabilitative Sciences, INC | $14.65 | 2021 | |
| Valinor Pharma, LLC | $14.16 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kenney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.